Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Effect of antisecretory factor, given as a food supplement to adult patients with severe traumatic brain injury (SASAT) : protocol for an exploratory randomized double blind placebo-controlled trial

Cederberg, David LU ; Harrington, Bradley M ; Vlok, Adriaan Johannes and Siesjö, Peter LU orcid (2022) In Trials 23(1).
Abstract

BACKGROUND: Traumatic brain injury (TBI) constitutes a global epidemic. Overall outcome is poor, with mortality ranging from 10 to 70% and significant long-term morbidity. Several experimental reports have claimed effect on traumatic edema, but no clinical trials have shown effect on edema or outcome. Antisecretory factor, an endogenous protein, is commercially available as Salovum®, which is classified as a medical food by the European Union and has shown effect in experimental trauma models and feasibility with signs of effect in 2 pilot case series. The aim of this study is to assess the effect of antisecretory factor in adult patients with severe traumatic brain injury as measured by 30-day mortality, treatment intensity level... (More)

BACKGROUND: Traumatic brain injury (TBI) constitutes a global epidemic. Overall outcome is poor, with mortality ranging from 10 to 70% and significant long-term morbidity. Several experimental reports have claimed effect on traumatic edema, but no clinical trials have shown effect on edema or outcome. Antisecretory factor, an endogenous protein, is commercially available as Salovum®, which is classified as a medical food by the European Union and has shown effect in experimental trauma models and feasibility with signs of effect in 2 pilot case series. The aim of this study is to assess the effect of antisecretory factor in adult patients with severe traumatic brain injury as measured by 30-day mortality, treatment intensity level (TIL), and intracranial pressure (ICP).

METHODS/DESIGN: This is a single-center, double-blind, randomized, placebo-controlled clinical phase 2 trial, investigating the clinical superiority of Salovum® given as a food supplement to adults with severe TBI (GCS < 9), presenting to the trauma unit at Tygerberg University Hospital, Cape Town, South Africa, that are planned for invasive ICP monitoring and neurointensive care, will be screened for eligibility, and assigned to either treatment group (n = 50) or placebo group (n = 50). In both groups, the primary outcome will be 30-day mortality, recorded via hospital charts, follow-up phone calls, and the population registry. Secondary outcomes will be treatment intensity level (TIL), scored from hospital charts, and ICP registered from hospital data monitoring.

TRIAL REGISTRATION: ClinicalTrials.gov NCT03339505 . Registered on September 17, 2017. Protocol version 3.0 from November 13, 2020.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Brain Injuries, Traumatic/drug therapy, Clinical Trials, Phase II as Topic, Dietary Supplements, Humans, Neuropeptides/therapeutic use, Randomized Controlled Trials as Topic, South Africa
in
Trials
volume
23
issue
1
article number
340
publisher
BioMed Central (BMC)
external identifiers
  • pmid:35461285
  • scopus:85128802036
ISSN
1745-6215
DOI
10.1186/s13063-022-06275-z
language
English
LU publication?
no
additional info
© 2022. The Author(s).
id
c82cdfeb-fbd2-410a-83c9-b8480b506ba1
date added to LUP
2024-02-12 15:13:11
date last changed
2024-02-15 14:54:35
@article{c82cdfeb-fbd2-410a-83c9-b8480b506ba1,
  abstract     = {{<p>BACKGROUND: Traumatic brain injury (TBI) constitutes a global epidemic. Overall outcome is poor, with mortality ranging from 10 to 70% and significant long-term morbidity. Several experimental reports have claimed effect on traumatic edema, but no clinical trials have shown effect on edema or outcome. Antisecretory factor, an endogenous protein, is commercially available as Salovum®, which is classified as a medical food by the European Union and has shown effect in experimental trauma models and feasibility with signs of effect in 2 pilot case series. The aim of this study is to assess the effect of antisecretory factor in adult patients with severe traumatic brain injury as measured by 30-day mortality, treatment intensity level (TIL), and intracranial pressure (ICP).</p><p>METHODS/DESIGN: This is a single-center, double-blind, randomized, placebo-controlled clinical phase 2 trial, investigating the clinical superiority of Salovum® given as a food supplement to adults with severe TBI (GCS &lt; 9), presenting to the trauma unit at Tygerberg University Hospital, Cape Town, South Africa, that are planned for invasive ICP monitoring and neurointensive care, will be screened for eligibility, and assigned to either treatment group (n = 50) or placebo group (n = 50). In both groups, the primary outcome will be 30-day mortality, recorded via hospital charts, follow-up phone calls, and the population registry. Secondary outcomes will be treatment intensity level (TIL), scored from hospital charts, and ICP registered from hospital data monitoring.</p><p>TRIAL REGISTRATION: ClinicalTrials.gov NCT03339505 . Registered on September 17, 2017. Protocol version 3.0 from November 13, 2020.</p>}},
  author       = {{Cederberg, David and Harrington, Bradley M and Vlok, Adriaan Johannes and Siesjö, Peter}},
  issn         = {{1745-6215}},
  keywords     = {{Adult; Brain Injuries, Traumatic/drug therapy; Clinical Trials, Phase II as Topic; Dietary Supplements; Humans; Neuropeptides/therapeutic use; Randomized Controlled Trials as Topic; South Africa}},
  language     = {{eng}},
  month        = {{04}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{Trials}},
  title        = {{Effect of antisecretory factor, given as a food supplement to adult patients with severe traumatic brain injury (SASAT) : protocol for an exploratory randomized double blind placebo-controlled trial}},
  url          = {{http://dx.doi.org/10.1186/s13063-022-06275-z}},
  doi          = {{10.1186/s13063-022-06275-z}},
  volume       = {{23}},
  year         = {{2022}},
}